CAPRELSA®( vandetanib )

Drug CAPRELSA® vandetanib Caprelsa Overview This is a summary of the European public assessment report (EPAR) for Caprelsa. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Caprelsa. How is Caprelsa used? […]

TORISEL® (temsirolimus)

Drug TORISEL® temsirolimus Torisel Overview Torisel is a medicine used to treat patients with the following types of cancer: advanced renal cell carcinoma (a kidney cancer). ‘Advanced’ means that the cancer has started to spread; mantle cell lymphoma (a cancer of B cells, a type of white blood cell). Torisel is used in adults when […]

VOTRIENT® (pazopanib)

Drug VOTRIENT® pazopanib Votrient Overview This is a summary of the European public assessment report (EPAR) for Votrient. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Votrient. How is Votrient used? Treatment with Votrient […]

CABOMETYX® (cabozantinib)

Drug CABOMETYX® cabozantinib Cabometyx Overview Cabometyx is a cancer medicine used to treat adults with: advanced renal cell carcinoma (a kidney cancer). It is used in patients who have been previously treated with a type of cancer medicine called ‘vascular endothelial growth factor (VEGF) inhibitor’. It is also used in patients who have not had […]

INLYTA® (axitinib)

Drug INLYTA® axitinib Inlyta Overview This is a summary of the European public assessment report (EPAR) for Inlyta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Inlyta. How is Inlyta used? Treatment with Inlyta […]

SUTENT® (sunitinib)

Drug SUTENT® sunitinib Sutent Overview This is a summary of the European public assessment report (EPAR) for Sutent. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sutent. How is Sutent used? Treatment with Sutent […]

MVASI® (bevacizumab)

Drug MVASI® Bevacizumab Mvasi Overview This is a summary of the European public assessment report (EPAR) for Mvasi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Mvasi. For practical information about using Mvasi, […]

YERVOY® (ipilimumab)

Drug YERVOY® ipilimumab Yervoy Overview Yervoy is a cancer medicine used in adults and adolescents from 12 years of age with advanced melanoma (a type of skin cancer) and in adults with advanced renal cell carcinoma (a kidney cancer). Yervoy is usually used in combination with another medicine, nivolumab, but can also be used on […]

AVASTIN® (bevacizumab)

Drug AVASTIN® bevacizumab Avastin Overview This is a summary of the European public assessment report (EPAR) for Avastin. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Avastin. For practical information about using Avastin, […]

AFINITOR® (everolimus)

Drug AFINITOR® everolimus Afinitor Overview Afinitor is a cancer medicine used to treat the following cancers: breast cancer that is advanced (has started to spread) in women who have been through their menopause. Afinitor is used in breast cancer that is ‘hormone receptor-positive’ (when the cancer cells have oestrogen receptors on their surface) and ‘HER2/neu […]